CL2018002084A1 - Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1. - Google Patents

Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1.

Info

Publication number
CL2018002084A1
CL2018002084A1 CL2018002084A CL2018002084A CL2018002084A1 CL 2018002084 A1 CL2018002084 A1 CL 2018002084A1 CL 2018002084 A CL2018002084 A CL 2018002084A CL 2018002084 A CL2018002084 A CL 2018002084A CL 2018002084 A1 CL2018002084 A1 CL 2018002084A1
Authority
CL
Chile
Prior art keywords
hiv
inhibitors
triterpenoids
modified
compounds
Prior art date
Application number
CL2018002084A
Other languages
English (en)
Inventor
Sing-Yuen Sit
Yan Chen
Jie Chen
Jacob Swidorski
Brian Lee Venables
Ny Sin
Alicia Regueiro-Ren
Richard A Hartz
Ira B Dicker
Nicholas Meanwell
Beata Nowicka-Sans
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of CL2018002084A1 publication Critical patent/CL2018002084A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

SE EXPONEN COMPUESTOS QUE TIENEN PROPIEDADES FARMACOLÓGICAS Y QUE AFECTAN A LA BIOACTIVIDAD, SUS COMPOSICIONES FARMACÉUTICAS Y PROCEDIMIENTOS DE USO. EN PARTICULAR, SE PROPORCIONAN DERIVADOS DE ÁCIDO BETULÍNICO QUE POSEEN ACTIVIDAD ANTIVÍRICA ÚNICA COMO INHIBIDORES DE LA MADURACIÓN DEL VIH, TAL COMO SE REPRESENTA MEDIANTE LOS COMPUESTOS DE FÓRMULA I, QUE SON ÚTILES PARA EL TRATAMIENTO DEL VIH Y DEL SIDA.
CL2018002084A 2016-02-04 2018-08-02 Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1. CL2018002084A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662291298P 2016-02-04 2016-02-04

Publications (1)

Publication Number Publication Date
CL2018002084A1 true CL2018002084A1 (es) 2018-09-21

Family

ID=57995251

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002084A CL2018002084A1 (es) 2016-02-04 2018-08-02 Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1.

Country Status (38)

Country Link
US (4) US10421774B2 (es)
EP (2) EP3411381B1 (es)
JP (1) JP6735837B2 (es)
KR (1) KR20180105229A (es)
CN (1) CN109153700B (es)
AR (1) AR107512A1 (es)
AU (1) AU2017215529B2 (es)
BR (1) BR112018015629B1 (es)
CA (1) CA3013417C (es)
CL (1) CL2018002084A1 (es)
CO (1) CO2018008157A2 (es)
CR (1) CR20180387A (es)
CY (1) CY1124353T1 (es)
DK (1) DK3411381T3 (es)
DO (1) DOP2018000174A (es)
EA (1) EA036211B1 (es)
ES (2) ES2862325T3 (es)
HK (1) HK1256866A1 (es)
HR (1) HRP20210502T1 (es)
HU (1) HUE054337T2 (es)
IL (1) IL260741B (es)
JO (1) JOP20170029B1 (es)
LT (1) LT3411381T (es)
MA (2) MA43960B1 (es)
MD (1) MD3411381T2 (es)
MX (1) MX2018009514A (es)
PE (1) PE20181355A1 (es)
PL (1) PL3411381T3 (es)
PT (1) PT3411381T (es)
RS (1) RS61746B1 (es)
RU (1) RU2716502C2 (es)
SG (1) SG11201806388XA (es)
SI (1) SI3411381T1 (es)
TW (1) TWI719126B (es)
UA (1) UA123867C2 (es)
UY (1) UY37109A (es)
WO (1) WO2017134596A1 (es)
ZA (1) ZA201805044B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US20210347813A1 (en) 2018-04-24 2021-11-11 Viiv Healthcare Uk (No. 5) Limited Compounds with hiv maturation inhibitory activity
WO2021116872A1 (en) 2019-12-09 2021-06-17 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
GB0301227D0 (en) 2003-01-20 2003-02-19 Keen Group Ltd Seating apparatus
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
RU2387665C2 (ru) 2004-03-17 2010-04-27 Панакос Фармасьютикалз, Инк. Фармацевтические соли 3-о-(3', 3'-диметилсукцинил)бетулиновой кислоты
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US20090105203A1 (en) 2006-10-16 2009-04-23 Myriad Genetics, Incorporated Compounds for treating viral infections
WO2009100532A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
FR2956034B1 (fr) 2010-02-09 2012-02-10 Thales Sa Dispositif d'entrainement pour des joueurs de rugby
JP5755731B2 (ja) 2010-06-04 2015-07-29 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｉｖ成熟阻害剤としての修飾ｃ−３ベツリン酸誘導体のｃ−２８アミド
WO2011153315A1 (en) 2010-06-04 2011-12-08 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
DE102010017786A1 (de) 2010-07-07 2012-01-12 Continental Reifen Deutschland Gmbh Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung
KR101886467B1 (ko) * 2011-01-31 2018-08-07 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드
EP2670764B1 (en) 2011-01-31 2015-09-02 Bristol-Myers Squibb Company C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors
RU2613554C2 (ru) * 2011-12-14 2017-03-17 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Пропеноатные производные бетулина
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9378035B2 (en) 2012-12-28 2016-06-28 Commvault Systems, Inc. Systems and methods for repurposing virtual machines
EP2953960A1 (en) * 2013-02-06 2015-12-16 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
BR112015019590A2 (pt) * 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
CN104877015B (zh) * 2014-02-28 2019-02-01 中国人民解放军军事医学科学院毒物药物研究所 一种三萜-多肽缀合物、其药物组合物及用途
AR101077A1 (es) 2014-04-11 2016-11-23 Bristol Myers Squibb Co Triterpenoides con actividad inhibidora de la maduración de hiv
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
PL3411358T3 (pl) 2016-02-04 2022-02-28 Takeda Pharmaceutical Company Limited Podstawiony związek piperydynowy i jego zastosowanie
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1

Also Published As

Publication number Publication date
CA3013417A1 (en) 2017-08-10
CY1124353T1 (el) 2022-07-22
KR20180105229A (ko) 2018-09-27
BR112018015629A2 (pt) 2018-12-26
RU2716502C2 (ru) 2020-03-12
EP3411381B1 (en) 2021-01-20
AU2017215529A8 (en) 2018-08-30
PL3411381T3 (pl) 2021-09-13
JP6735837B2 (ja) 2020-08-05
US20230295220A1 (en) 2023-09-21
TWI719126B (zh) 2021-02-21
MX2018009514A (es) 2018-09-05
EP3831839B1 (en) 2023-07-26
RU2018130181A (ru) 2020-03-05
AU2017215529A1 (en) 2018-08-23
MD3411381T2 (ro) 2021-07-31
PE20181355A1 (es) 2018-08-22
SI3411381T1 (sl) 2021-04-30
CA3013417C (en) 2024-01-02
US10421774B2 (en) 2019-09-24
CR20180387A (es) 2018-09-20
ZA201805044B (en) 2020-08-26
AR107512A1 (es) 2018-05-09
CN109153700A (zh) 2019-01-04
SG11201806388XA (en) 2018-08-30
MA53358A (fr) 2021-07-21
MA43960A (fr) 2018-12-12
HRP20210502T1 (hr) 2021-05-14
LT3411381T (lt) 2021-04-26
RU2018130181A3 (es) 2020-03-05
DOP2018000174A (es) 2018-10-31
HUE054337T2 (hu) 2021-08-30
EP3831839A2 (en) 2021-06-09
EA201891649A1 (ru) 2019-02-28
US20210323997A1 (en) 2021-10-21
PT3411381T (pt) 2021-03-18
CO2018008157A2 (es) 2018-08-21
JOP20170029B1 (ar) 2021-08-17
ES2957767T3 (es) 2024-01-25
JP2019504104A (ja) 2019-02-14
EP3831839A3 (en) 2021-07-21
US20190359647A1 (en) 2019-11-28
DK3411381T3 (da) 2021-04-06
TW201739757A (zh) 2017-11-16
CN109153700B (zh) 2021-03-09
RS61746B1 (sr) 2021-05-31
US11084845B2 (en) 2021-08-10
IL260741B (en) 2020-04-30
HK1256866A1 (zh) 2019-10-04
BR112018015629B1 (pt) 2023-10-24
MA43960B1 (fr) 2021-02-26
ES2862325T3 (es) 2021-10-07
UY37109A (es) 2017-09-29
EP3411381A1 (en) 2018-12-12
AU2017215529B2 (en) 2019-01-31
EA036211B1 (ru) 2020-10-14
UA123867C2 (uk) 2021-06-16
WO2017134596A1 (en) 2017-08-10
US20190031709A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
UY33886A (es) Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del vih
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CL2018002084A1 (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1.
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
UY36285A (es) Compuestos que inhiben la proteína mcl-1
UY35213A (es) Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
CL2018000363A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana.
CL2017002034A1 (es) Nueva triterpenona c-3 con derivados de amida inversa c-17 como inhibidores de vih.
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
CL2012003006A1 (es) Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer.
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CL2017000707A1 (es) Derivados de nucleosidos sustituidos de 4'-vinilo como inhibidores de la replicación del arn del virus sincicial respiratorio
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
PH12018501640A1 (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
BR112017009852A2 (pt) composto, composição, e, usos de um composto
BR112017009853A2 (pt) composto, composição, uso de uma quantidade melhoradora de hiv de um composto